Aratana Therapeutics, Inc.
PETX
PETX was delisted on the 17th of July, 2019.
0 hedge funds and large institutions have $0 invested in Aratana Therapeutics, Inc. in 2019 Q4 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 2 closing their positions.
100% less funds holding
Funds holding: 2 → 0 (-2)
100% less capital invested
Capital invested by funds: $267K → $0 (-$267K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DC
Davenport & Co
Richmond,
Virginia
|
-$262K |
| 2 |
ASN
Advisory Services Network
Atlanta,
Georgia
|
-$5K |
PETX Hedge Fund Activity: Q4 2019 in Review
0 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Aratana Therapeutics, Inc. (PETX) for Q4 2019, worth a combined $0 — down 100% from $267K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of PETX and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Davenport & Co, exiting entirely with an estimated $262K sold.
- 0 institutional investors held Aratana Therapeutics, Inc. (PETX) as of Q4 2019, down from 2 in Q3 2019.
- Funds reported $0 of Aratana Therapeutics, Inc. stock for Q4 2019, down 100% quarter-over-quarter.
- 0 funds opened new Aratana Therapeutics, Inc. positions in Q4 2019 and 2 closed out, a net change of -2 holders.
- The largest Aratana Therapeutics, Inc. seller in Q4 2019 was Davenport & Co, an estimated $262K sold.
Based on aggregated 13F filings for Q4 2019.